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SUMMARY
In glioblastoma, invasion and proliferation are pre-
sumed to be mutually exclusive events; however,
the molecular mechanisms that mediate this
switch at the cellular level remain elusive. Previously,
we have shown that phospho-OLIG2, a central-
nervous-system-specific transcription factor, is
essential for tumor growth and proliferation. Here,
we show that the modulation of OLIG2 phosphoryla-
tion can trigger a switch between proliferation
and invasion. Glioma cells with unphosphorylated
OLIG2S10, S13, S14 are highly migratory and invasive,
both in vitro and in vivo. Mechanistically, unphos-
phorylated OLIG2 induces TGF-b2 expression and
promotes invasive mesenchymal properties in gli-
oma cells. Inhibition of the TGF-b2 pathway
blocks this OLIG2-dependent invasion. Furthermore,
ectopic expression of phosphomimetic Olig2 is suffi-
cient to block TGF-b2-mediated invasion and reduce
expression of invasion genes (ZEB1 and CD44). Our
results not only provide a mechanistic insight into
how cells switch from proliferation to invasion but
also offer therapeutic opportunities for inhibiting
dissemination of gliomas.
INTRODUCTION
Glioblastoma (GBM) is the most aggressive, infiltrative, and le-
thal brain tumor in adults, with a median survival of 9–14 months
after diagnosis (Furnari et al., 2007; Maher et al., 2001; Ostrom
et al., 2015). Although relatively rare, these tumors are associ-
ated with high mortality rates, mainly due to their invasive nature
and resistance to radiotherapy and chemotherapy. The tumors
almost always recur, and no standard-of-care treatment is avail-
able for recurrent GBM (Hess et al., 1999; Wong et al., 1999;
Weller et al., 2013). One reason for tumor recurrence is the pres-
ence of highly tumorigenic and invasive cells that infiltrate normal
brain parenchyma and evade surgical resection (Giese et al.,
2003). Hence, the development of effective therapies for GBM
requires an understanding of the mechanisms that trigger inva-
sive phenotypes in GBM tumors.
The GBM peritumoral zone is composed of invasive cells with
distinct molecular phenotypes that are highly migratory and that
infiltrate the healthy brain (Giese et al., 1996; Glas et al., 2010; Sil-
ver et al., 2013). Several studies have shown that cell prolifera-
tion and migration/invasion are mutually exclusive events, with
proliferating cells being less motile and with rapidly moving cells
proliferating slowly (Giese, 2003; Giese et al., 1996; Cayre et al.,
2009). Genes involved in cell migration have been shown to be
upregulated in invading cells at the tumor rim, whereas prolifer-
ation genes are downregulated (Dhruv et al., 2013; Loftus et al.,
2012). This difference in gene expression suggests a possible
role for transcription factors (TFs) in modulating cellular pheno-
type from proliferation to invasion. Several TFs (e.g., ZEB1,
STAT3, C/EBPb, and TAZ) have been shown to play a critical
role in the induction of invasive mesenchymal phenotypes in
GBM cells (Carro et al., 2010; Siebzehnrubl et al., 2013). Herein,
we will demonstrate how a central nervous system (CNS)-spe-
cific TF, OLIG2, can promote either invasion or proliferation
based on its phosphorylation state.
Olig2 is a basic helix-loop-helix (bHLH) TF expressed in the
multipotent neural progenitor cells in the developing brain and
is required for the generation of oligodendrocytes and certain
subtypes of motor neurons (Meijer et al., 2012). During CNS
development, Olig2 performs two contrasting functions: early
on, Olig2 sustains the replication competence of progenitor
cells, and later, when a sufficient number of progenitor cells
are reached, Olig2 is required for cell-type specification of oligo-
dendrocytes and motor neurons (Meijer et al., 2012). In the adult
brain, Olig2 is not only expressed in mature oligodendrocytes
but is also expressed in the two proliferating populations of cells,
namely, the transit-amplifying type C cells and the NG2-positive
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glia (Meijer et al., 2012). A pathological correlate of this prolifer-
ative function of Olig2 is observed in high-grade gliomas. OLIG2
has been shown to be universally expressed in almost all diffuse
gliomas (Ligon et al., 2004; Lu et al., 2001). Apart from marking
glioma cells, Olig2 expression is required for glioma growth,
which has been both demonstrated in a genetically relevant mu-
rine model and in orthotopic patient-derived xenograft models
(Ligon et al., 2007; Mehta et al., 2011). Recently, OLIG2 was
shown to be a key TF required for reprogramming differentiated
glioma cells into highly tumorigenic glioma stem-like cells (GSCs)
(Suva` et al., 2014).
Olig2 is phosphorylated at the triple-serine motif (S10, S13,
and S14) near the amino terminus (pOlig2) (Sun et al., 2011).
The phosphorylation at these sites is developmentally regulated
and present in cycling neural progenitor cells, but not in mature
oligodendrocytes (Sun et al., 2011). Most GSCs express pOLIG2
at levels similar to those of cycling progenitor cells. Expression of
a triple-phosphomimetic (TPM)mutant of Olig2 leads to faster tu-
mor growth than does expression of a triple-phosphonull (TPN)
mutant in a genetically relevant murine glioma model. TPN-ex-
pressing cells are able to form tumors, but with longer latency
(Sun et al., 2011).
Recent studies have shown that Olig2 might play a role in
promoting migration/invasion in normal oligodendrocyte precur-
sor cells (OPCs), as well as in GSCs (Hornig et al., 2013;
Nevo et al., 2014). In addition, recent findings suggest that
both contrast-enhancing GBM tumor core, as well as non-
enhancing tumor margins, express high levels of Olig2 (Venere
et al., 2015). An important question that then arises is how a sin-
gle TF, such as OLIG2, regulates these distinct transcriptional
programs of proliferation and invasion. In this study, we demon-
strate how the N-terminal phosphorylation of OLIG2 can regulate
cell invasion through its transcriptional regulation of the TGF-b2
pathway. We show that cells expressing unphosphorylated
Olig2S10, 13, 14 or low levels of pOLIG2 (pOLIG2low) are highly
invasive. Furthermore, we find that inhibition of the TGF-b2
pathway suppresses OLIG2-mediated invasion.
RESULTS
Olig2 Is Required for Migration/Invasion of Both Normal
Neural Stem Cells and Glioma Stem-like Cells
To interrogate the role of Olig2 in promoting cell migration/inva-
sion, we comparedmurineOlig2-KO (Olig2-knockout) andOlig2-
WT (Olig2-wild-type) using an in vitro migration assay. We
utilized previously characterized murine glioma stem-like cells
(mGSCs) (Ink4a/Arf/ hEGFRvIII) and normal murine neural
stem cells (mNSCs) (Ligon et al., 2007). Both mNSCs and
mGSCs expressing wild-type Olig2 showed increased capacity
of migration compared to cells without Olig2 (Olig2-KO) (Figures
1A and 1B). There was no significant difference in cell viability or
substrate attachment between Olig2-WT and Olig2-KO mNSCs
and mGSCs in samples collected 2 hr post-plating (Figure S1A).
However, after 24 hr, Olig2-WT cells proliferate at slightly higher
(but significant) efficiency compared to Olig2-KO cells (Fig-
ure S1B). Next, through a 3D Matrigel matrix, we assessed
whether Olig2 expression is also required for cell invasion. As
shown in Figures 1C and 1D, under both normal and oncogenic
backgrounds, Olig2-WT cells have a significantly higher capa-
bility to invade through a 3D matrix than do Olig2-KO cells. It is
known that the absence of Olig2 produces a small but significant
effect on the proliferation rate of normal and oncogenic neuro-
spheres (Ligon et al., 2007). Thus, the question is whether the
increase in cell invasion is due to the increased proliferation of
Olig2-WT cells. However, considering that Olig2-WT and
Olig2-KO have doubling times of 33 and 43 hr (Ligon et al.,
2007), respectively, the increased invasion observed after 24 hr
is highly unlikely to be solely due to higher proliferation rates.
N-Terminal Phosphorylation of Olig2 at a Triple-Serine
Motif Affects Migration/Invasion of mNSCs and mGSCs
We used previously established Olig2-TPM and TPNmutant-ex-
pressing cell lines to examine the effect of Olig2 phosphorylation
on the ability of mNSCs and mGSCs to migrate/invade (Sun
et al., 2011). We found that highly proliferative TPM-expressing
murine cells migrate and invade significantly more slowly than
TPN-expressing cells (Figures 1E–1H). Control experiments
confirmed that the differences inmigration and invasion between
TPM and TPN mutants are independent of cell viability or loss of
attachment (Figures S1C and S1D). As previously observed (Sun
et al., 2011), there were significantly more TPMcells after 24 hr of
seeding than TPN cells. These data demonstrate that both
mNSCs and mGSCs expressing the unphosphorylated form of
Olig2 have increased migration/invasion ability in vitro.
Phosphorylation Level of OLIG2 at Triple Serine Motif
Dictates Migration/Invasion Ability of Human GSCs
Our previous studies show that OLIG2 is phosphorylated at the
N terminus inmost proliferating GBMcells grown in the presence
of growth factors (Sun et al., 2011). However, the phosphoryla-
tion levels significantly vary among various human patient-
derived GBM GSCs (hGSCs), as seen previously (Sun et al.,
2011), and from the pOLIG2/total OLIG2 (tOLIG2) levels across
the six hGSC lines used in this study (Figures 2A and S2A; Table
Figure 1. Phosphorylation Status of Olig2 Affects Invasion/Migration of mNSCs and mGSCs
(A–D) Olig2-WT mNSCs and mGSCs are more migratory and invasive than Olig2-KO cells. Representative images of the central zone to which cells migrate
at 0 and 24 hr (A) and quantification of the total number of migrated cells at 24 hr (B). Inset shows the western blot data for Olig2 and Vinculin. Representative
images are from transwell assays of mNSCs and mGSCs with or without Olig2 after 24 hr post-seeding (C) and show quantification of the total number of DAPI-
stained nuclei (D).
(E–H) In vitromigration/invasion assays of mNSC- andmGSC-expressingOlig2 phosphomutants. mNSC- ormGSC-expressing TPNmutant shows the increased
migration (E and F) and invasion (G and H) compared to the TPM-expressing cells. (G) IRS quantification of Ki67+ (red) cells at core, edge and rim regions. (H) IRS
quantification of pSMAD2+ (green) cells at core, edge and rim regions. Scale bars, 100 mm. Inset in (F) showswestern blot probed for Olig2 and Vinculin. For all bar
graphs, the data represent mean ± SD of three independent experiments. *p < 0.05; **p < 0.01; ***p < 0.001.
See also Figure S1.
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S1). As shown in Figures 2B and 2C, the phosphorylation levels
of OLIG2 affect the migration/invasion capacity of multiple
hGSCs. There is a significant difference in the number of
migrating hGSCs with pOLIG2high (BT145 and GB7, labeled in
blue) than hGSCs with pOLIG2low (BT147, GB3, GB16, and
GB42). We observed similar differences between hGSCs in their
ability to invade the 3D matrix (Figures 2D and 2E). As expected,
hGSCs with pOLIG2high were more proliferative than those with
pOLIG2low, and no difference was observed in substrate attach-
ment and cell viability (Figures S2B and S2C).
To determine whether increased invasion in hGSCs is depen-
dent on OLIG2 expression, we transduced three hGSCs (GB7,
GB16, and BT147) with either a control non-target short hairpin
RNA (shNT) or shOLIG2. Knockdown of OLIG2 significantly
decreased the ability of all three hGSCs to invade (Figures 2F,
2G, and S2D). Knockdown with a second hairpin targeting
different regions of OLIG2 ORF confirmed that the decrease in
invasion was not an off-target effect (Figure S2E). Thus, it can
be concluded that OLIG2 expression promotes cell migration/in-
vasion in hGSCs and that the phosphorylation status of OLIG2 is
critical in determining their invasive properties in vitro.
Glioma Cells Expressing Unphosphorylated OLIG2 Are
Invasive
We compared the peritumoral rims in tumors induced by TPN-
and TPM-expressing mGSCs to assess whether unphosphory-
lated Olig2 expression promotes invasion in vivo. As indicated
in Figures 3A, 3B, and S3A–S3D, TPN cells could be detected
in the normal brain regions distal from the tumor core, whereas
TPM cells showed restricted invasion of the brain parenchyma.
Quantification of the number of cells that invaded the adjacent
areas, e.g., the tumor rim, ventricles, the white matter tracts,
and the dentate gyrus (DG) region, clearly demonstrated the
invasive nature of TPN cells (Figure 3C). In addition, TPN cells
showed strong expression of Snail/Slug (EMTmarker) compared
to TPM-induced tumors (Figure S3E).
In order to further strengthen our observations with genetically
defined murine glioma models and Olig2 phosphomutants, we
compared patient-derived xenograft (PDX) tissues from the
hGSC lines BT147 (pOLIG2low) and BT145 (pOLIG2high) and
probed them with the stem cell marker VIMENTIN (VIM) to track
hGSCs. Immunostaining of the BT147 xenograft revealed exten-
sive infiltration of tumor cells throughout the brain parenchyma,
while BT145 cells were comparatively more localized (Figures
3D and 3E). To confirm that the VIM+ cells were indeed tumor
cells, we co-stained them with a human-specific NESTIN anti-
body that colocalized with VIM in both BT147 andBT145 tumors,
except in the ventricular regions of BT145 tumor (Figures 3F and
3G). VIM+ and NESTIN+ BT147 cells were detected within the
DG area as well (Figure S3F). Furthermore, we saw strong
ZEB1 expression in the invasive BT147 xenograft, including the
ventricular and DG areas (Figures 3H, 3I, and S3G), but only a
few ZEB1+ cells were seen in the BT145 tumor tissue.
To further examine differences in tumor cell dispersion be-
tween pOLIG2high and pOLIG2low hGSCs, we examined brain tis-
sues from GB3, BT145, and GB16 PDXs at an early time point
(3 weeks) post-implantation. The pOLIG2low lines GB3 and
GB16 cells migrated significantly further from the graft site,
mostly along the white matter tracts, compared to pOLIG2high
BT145 cells, which were restricted to the site of injection (Figures
4A–4E and S4A). These data strongly support our claim that
pOLIG2low hGSCs are highly invasive, both in vitro and in vivo.
To analyze the localization of phosphorylated and total OLIG2
within human GBM specimens, we stained fresh frozen tissue
sections from multiple GBM patients for pOLIG2, tOLIG2, and
Ki67. As previously reported, we found that almost all Ki67+ cells
are OLIG2+; however, a larger percentage (70%) of OLIG2+
cells do not express Ki67 (Figures 4F and 4G) (Ligon et al.,
2004, 2007). Using our highly specific pOLIG2 antibody,we found
that pOLIG2 co-localizes with the proliferative marker Ki67 in
90%of cells (Figures 4H and 4I), confirming our previous obser-
vations (Ligon et al., 2007; Sun et al., 2011). Within multiple GBM
tissues,we foundadecreasinggradient of pOLIG2+cells from the
tumor core to the invasive edge (Figures 4I and S4B–S4D). These
data support our hypothesis that proliferating cells express
pOLIG2, and invading cells express unphosphorylated OLIG2.
To assess the distribution of OLIG2+ and pOLIG2+ cells within
GBM tumors, we probed a GBM tissue microarray (TMA) com-
prising 33 matched GBM tumor core, edge, and rim tissues (Kislin
et al., 2009). Sinceour pOLIG2antibodydoesnotworkonparaffin-
embedded tissues (and there is 90% colocalization between
pOLIG2 and Ki67), we utilized Ki67 staining as a surrogate for
pOLIG2 staining on paraffin-embedded tissues. In a vast majority
of GBM tissues, OLIG2+ cells were detected at the tumor core,
edge, and infiltrative tumor rim, whereas Ki67+ (pOLIG2) cells
were predominantly found at the tumor core (Figures 4J and 4K).
These data strongly suggest that Ki67+ (pOLIG2+) proliferating
cells are mainly present at the tumor core, whereas unphosphory-
lated OLIG2-expressing cells are present throughout the tumor.
OLIG2 Phosphorylation Regulates Expression of
Invasion Genes
Since OLIG2 is a TF, we investigated the effect of OLIG2 phos-
phorylation on genes involved in invasion, cell-cycle regulation,
Figure 2. N-Terminal Phosphorylation of OLIG2 Affects Invasion/Migration in hGSCs
(A) Indicated hGSC lysates were analyzed for the ratio of pOLIG2 over tOLIG2 by immunoblotting with pOLIG2, OLIG2, and VINCULIN antibodies. pOLIG2high
hGSCs are labeled in blue.
(B–E) In vitro cell migration assays show that cell lines with pOLIG2low (BT147, GB3, GB16, and GB42) are more migratory (B and C) and invasive (D and E)
compared to cell lines with pOLIG2high (BT145 and GB7).
(F and G) Knockdown of OLIG2 reduces glioma cell invasion. Invasion assay was performed 72 hr post-transduction of GB7 and GB16 cells with either control
non-target hairpin (shNT) or shOlig2-expressing lentivirus (F). Quantification of the total number of invading cells after knockdown ofOLIG2 (G) is shown.Western
blot analysis afterOLIG2 knockdown in GB7 andGB16 cells (G, inset). Scale bars, 100 (B) and 50 mm (D and F). For all bar graphs, the data representmean ±SD of
three independent experiments.*p < 0.05; **p < 0.01; ***p < 0.001.
See also Figure S2.
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and proliferation. We performed qRT-PCR analysis of invasion-
related markers enriched for genes associated with an epithe-
lial-to-mesenchymal transition (EMT) (e.g., TWIST1, CD44,
TGFb2, CREB1, and ZEB1) (Kalluri and Weinberg, 2009; Polyak
and Weinberg, 2009) in mGSCs and hGSCs. Interestingly, we
found that invasion genes are upregulated in TPN-expressing
mGSCs compared to TPM-expressing cells. Expression of
Tgfb2, Zeb1, and Cd44 was upregulated in TPN-expressing
mGSCs, and proliferation markers (Egfr and Cdk6) were highly
expressed in TPM-expressing cells (Figures S5A and S5B).
Next, we examined whether this observation also holds true in
hGSCs and whether it is dependent on OLIG2 phosphorylation
status. qRT-PCR analysis showed a robust transcriptional upre-
gulation of invasion genes in hGSCs with pOLIG2low (BT147 and
GB16) compared to hGSCs with pOLIG2high (BT145 and GB7)
(Figures 5A and 5B). In contrast, proliferation and cell-cycle-
associated genes were upregulated in pOLIG2high hGSCs (Fig-
ures S5C and S5D). To further confirm that OLIG2 regulates
the expression of invasion genes, we ablated OLIG2 expression
in BT147, GB16, and GB7 cells. shRNA-mediated knockdown of
OLIG2 led to a significant decrease in the expression of invasion
genes in all three hGSCs, suggesting that OLIG2 is required for
the regulation of expression of these genes in hGSCs (Figures
5C, 5D, and S5E). Previous studies have shown that ZEB1 regu-
lates OLIG2 expression. Our data demonstrate a reciprocal
regulation of ZEB1 by OLIG2. Analysis of published chromatin
immunoprecipitation sequencing (ChIP-seq) data (Suva` et al.,
2014) showed that OLIG2 associated with an enhancer region
of the ZEB1 gene, which is also enriched for H3K27ac mark.
Directed ChIP analysis in the GB16 line (pOLIG2low) confirmed
that OLIG2 associated with the ZEB1 enhancer region and that
the region is alsomarked by H3K27ac (Figure S5F). Furthermore,
ZEB1 expression is dramatically reduced after knockdown of
OLIG2 in two hGSCs (GB3 and GB16) (Figure S5G). Collectively,
these data show that unphosphorylated Olig2, or pOLIG2low, in-
duces the expression of migration/invasion genes.
OLIG2 Promotes Invasion by Upregulating TGFb2
Expression
To scrutinize the downstream mechanisms through which
OLIG2 governs invasion, we focused our attention on TGF-b2
for two reasons: Tgfb2 is a direct genetic target of Olig2 in normal
neural progenitor cells (Meijer et al., 2014), and the TGF-b
pathway plays an important role in the invasion of tumor cells
in several solid cancers, including GBM (Anido et al., 2010;
Rich, 2003; Weller et al., 2001; Wick et al., 2001). Analysis of
ChIP-seq tracks from Meijer et al. (2014) demonstrated that
both phosphorylated and unphosphorylated forms of Olig2
associate with the Tgfb2 locus (Figures 5E and 5F) and regulate
its expression in normal neural progenitor cells. A ChIP assay
with Olig2 and H3K27ac antibodies confirmed association of
both TPM and TPN mutants with Tgfb2 enhancer region in
mGSCs (Figure 5F), and we found significant enrichment of the
active enhancer histone mark (H3K27ac) at the Tgfb2 locus
(ChIP-seq track for H3K27ac fromMateo et al. 2015) in TPN cells
compared to that in TPM cells (Figures 5E and 5F).
By performing aChIP assay in hGSCs, we confirmed that TGF-
b2 is also a direct target of OLIG2 in hGSCs. OLIG2 associated
with TGFb2 locus in hGSCs within a region that has been shown
to be enriched for H3K27acmarks (Suva` et al., 2014) (Figures 5G
and 5H). We performed ELISA and a TGF-b growth inhibition
assay and found that pOLIG2low hGSCs and TPN-expressing
murine cells express high levels of TGF-b2 (Figures S6A and
S6B). Using TGF-b-sensitive CCL64 cells, we observed signifi-
cant growth inhibition after incubation with supernatants from
pOLIG2low hGSCs or TPN-expressing cells (Figures S6C and
S6D) compared to media alone or supernatant from pOLIG2high
and TPM-expressing cells. Pre-incubation of the supernatant
with the TGF-b2 antibody decreased growth inhibition. These
data suggest that Tgfb2 expression is upregulated in the pres-
ence of unphosphorylated Olig2.
We confirmed that the increase in TGF-b2 levels translates to
an increase in downstream TGF-b2 signaling. A TGF-b2 ligand
associates with TGF-b type I/II receptors and triggers phos-
phorylation of SMAD2/3 proteins. Phosphorylated SMAD2/3
(pSMAD2/3) then associates with SMAD4 to form a co-regula-
tory complex to activate downstream genetic targets (Schmierer
andHill, 2007).We did not detect any difference in TGF-b type I/II
receptor expression between pOLIG2high and pOLIG2low lines
(Figure S6E). However, we did detect high levels of pSMAD2
expression in oncogenic TPN-induced tumor tissues compared
to TPM-induced tumors (Figures 6A and 6B). The correlation be-
tween pSMAD2 levels and OLIG2 phosphorylation status in hu-
man tumors was confirmed by staining GB7 and GB16 patient
tissues with pSMAD2 and Ki67 antibodies. GB16 tissue showed
high levels of pSMAD2 compared to GB7 tissue (Figure S6F). We
confirmed this pattern by immunostaining of concomitant
sections from another fresh frozen human GBM tissue with
pSMAD2/Ki67 and pSMAD2/OLIG2 antibodies (Figure 6C). We
found very little overlap in pSMAD2 and Ki67 staining; however,
most OLIG2+ cells were pSMAD2+. Furthermore, we found that
hGSCs with pOLIG2low (GB16 and GB42) had higher levels of
Figure 3. Cells Expressing Unphosphorylated Olig2/ pOLIG2low Are Invasive
(A–C) mGSCs expressing the TPN mutant form highly infiltrative tumors compared to TPM-expressing mGSCs. Immunostaining for V5 epitope tag (green) in
murine TPM-expressing tumors (DAPI, blue) is shown (A). TPN-expressing tumors show infiltration of normal brain parenchyma and the ventricular and hip-
pocampal area (arrows) (B). (C) Scale bars, 1mm and 100 mm.Quantification of invading tumor cells at the peritumoral rim (the area comprised in white boxes in A
and B, ventricular areas, white matter tracts, and dentate gyrus regions (C) (arrows) is shown.
(D–I) Tumors induced by hGSCswith pOLIG2high (BT145) are less invasive compared to pOLIG2low (BT147). Immunostainingwith anti-VIMENTIN (green) in human
GBM xenograft tissues derived from BT145 (D) or BT147 (E) (DAPI, blue). Scale bars, 1 mm. Tracking tumor cells with human-specific NESTIN in PDX tissues
(F andG). Images of hNESTIN (red) and VIMENTIN (green) immunostaining in BT145 tumor tissue (zoom-in images of red boxed regions from (D) and (F). Images of
hNESTIN immunostaining in BT147 tumor tissue (zoom-in of red boxed regions from (E) and (G) (DAPI, blue). (H and I) Immunostaining with anti-hZEB1 in BT145
(H) and BT147 (I) tissues (zoom-in images of green boxed regions from D and E) is shown. For all bar graphs, data represent mean ± SD of three independent
experiments.*p < 0.05; **p < 0.01; ***p < 0.001.
See also Figure S3.
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pSMAD2 compared to the hGSCs with pOLIG2high (GB7) (Fig-
ure 6D). Ablation of OLIG2 (shOLIG2) in GB16 resulted in a
decrease in the levels of pSMAD2 (Figure 6E). Next, we probed
the TMA with pSMAD2/Ki67 antibodies to assess its localization
within the tumor. Similar to OLIG2+ cells (Figure 3), pSMAD2+
cells were found at the tumor core, edge, and rim regions (Fig-
ures 6F–6H). We observed no colocalization between pSMAD2
and Ki67. We also immunostained the TMA with OLIG2 and
pSMAD2 and found that OLIG2+ and pSMAD2+ cells were pre-
sent throughout the tumor (Figure S6G).
In breast cancer, TGF-b has been shown to increase the pop-
ulation of cells expressing CD44, a marker known to be upregu-
lated on induction of EMT (Gupta et al., 2009; Mani et al., 2008).
Recent studies have demonstrated that in GBM, TGF-b regu-
lates CD44 expression through induction of ID1 (inhibitor of
DNA binding 1 protein) (Anido et al., 2010). We found that an
OLIG2-mediated increase in TGFb2 expression also correlates
with increased CD44 levels. We probed for CD44 levels in the
hGSC line with pOLIG2high levels (GB7) and in two hGSC lines
with pOLIG2low (GB16 and GB42). Both the highly invasive
GB16 and GB42 lines have significantly higher levels of CD44
as compared to the less-invasive GB7 line. Furthermore, we
sorted for CD44high and CD44low populations by fluorescence-
activated cell-sorting from the GB42 GSC line and performed
qRT-PCR for migration /invasion genes (Figure S6H). We found
that the CD44high population expressed high levels of migra-
tion/invasion genes, including TGFb2, ZEB1, and VIM, as well
as OLIG2, in contrast to the CD44low population (Figure S6I).
Modulating TGF-b2 Levels Alters OLIG2-Mediated
Glioma Invasion
To determine whether TGF-b2 is the downstream effector of
OLIG2-mediated invasion in hGSCs with pOLIG2low, we treated
hGSCs (GB7 and GB16) with TGF-b receptor 1/2 inhibitor (TbRI)
(LY2109761) for 8 hr. In parallel experiments, we supplemented
the media with TGF-b2. The number of invading GB7 cells
increased significantly in presence of TGF-b2, a phenotype not
seen in GB16 cells (Figures 7A, 7B, S7A, and S7B). Following in-
hibitor treatment, there was a significant decrease in invasion in
the GB16 hGSC line; however, the TbRI only had a minor effect
on the less-invasive cell line (GB7) (Figures 7A, 7B, S7A, and
S7B). The concentration and duration of the TbRI treatment
and of TGF-b2 addition were sufficient to affect TGF-b signaling,
as seen by changes in pSMAD2/3 levels and by the expression of
invasion genes (Figures S7C and S7D). This effect was not due to
a decrease in cell viability following TbRI treatment (Figure S7E).
It is intriguing that we did not see an increase in the invasion of
GB16 in the presence of external TGF-b2. It is possible that either
the TGF-b2 signaling has reached its threshold or GB16 invasion
is independent of SMAD2 activation. To further confirm a direct
role of secreted TGF-b2, we pretreated pOLIG2high hGSCs (GB7
and BT145) with conditioned media from invasive hGSC lines
(GB16 and BT147) that have high levels of TGF-b2. As expected,
the number of cells invading through Matrigel increased when
grown in the presence of conditioned media from GB16 and
BT147 (Figures 7C, 7D, S7F, and S7G). To confirm that the
increased invasion was due to secreted TGF-b2 in the condi-
tioned media, we performed migration assay with cells pre-
treated with both GB16 and BT147-conditioned media and
TbRI. GB7 and BT145 cells failed to respond to conditioned
media and displayed a significant decrease in invasion in the
presence of the TbRI (Figures 7C, 7D, S7F, and S7G). These
data suggest that TGF-b2 is a downstream target of OLIG2
and that inhibition of the TGF-b pathway blocks OLIG2-mediated
invasion.
We tested whether OLIG2 phosphorylation/dephosphoryla-
tion is required for invasion by overexpressing TPM mutant of
Olig2 in the invasive GB16 cells and TPNmutant in the less-inva-
sive BT145 cells. Increased expression of TPM mutant in GB16
led to a dramatic decrease in the rate of invasion through Matri-
gel and decreased the expression of invasion markers (Figures
7E, S7H, and S7J). Conversely, overexpression of the TPN
form of Olig2 in BT145 led to increased invasion, as well as the
expression of invasion markers (Figures 7F, S7I, and S7K).
DISCUSSION
One of the hallmark features of glioblastoma is the infiltration of
tumor cells into normal brain regions. These invasive glioma cells
are the primary cause for tumor recurrence and poor prognosis
in GBM patients. Understanding the molecular mechanisms
and signaling pathways that trigger the invasive phenotype is
critical for the development of effective treatment of GBM.
Our findings provide insight into how the post-translational
modification of a single TF could possibly mediate the switch be-
tween proliferative and invasive phenotypes. We show that the
Figure 4. GBM Cells Expressing Unphosphorylated OLIG2 (or pOLIG2 low) Are Infiltrative and Are Found at the Tumor Core and Rim
(A–G) Analysis of tumor cell invasion in GBM xenograft models (GB3, GB16, and BT145) 3 weeks post-implantation. Immunostaining of tumor tissue with human-
specific mitochondrial antibody (green) in GB3 (A and A’), GB16 (B and B’), and BT145 (C and C’). Scale bars, 1 mm and 50 mm. Immunodetection of GB3 tumor
cells away from injection site within the white matter tracts (D and D’). Scale bars, 1 mm and 100 mm. The distance traveled by tumor cells from the graft site to the
anterior or posterior regions (n = 3 for each group) is shown (E). OLIG2+ cells are found throughout the tumor tissue. Quantification (F) and immunodetection (G) of
OLIG2+ (red) and Ki67+ (green) cells (both single- and double-labeled cells) in GBM patient tissue section. Proliferating cells in human GBM tissue express
pOLIG2.
(H and I) Quantification (H) and immunostaining (I) with pOLIG2 (red) and Ki67 (green) antibodies (both single- and double-labeled cells) in GBM patient tissue
sections (DAPI, blue). Images are representative of five GBM cases (G and I). For (F) and (H), the total number of cells from five individual fields per patient tumor
tissue section were counted. Scale bars, 100 mm. The analysis of glioma invasion TMA immunostained with OLIG2 and Ki67 antibodies is shown.
(J) Immune reactivity score (IRS) quantification of OLIG2+ and Ki67+ cells across 33 patient tumor core, edge, and rim in GBM patient TMA (both individual and
coexpressing cells).
(K) Representative images of OLIG2 (green) and Ki6 (red) staining from core, edge, and rim in TMA sections. Scale bar, 50 mm. For all bar graphs, data represent
mean ± SD from multiple experiments.*p < 0.05; **p < 0.01; ***p < 0.001.
See also Figure S4.
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Figure 5. OLIG2 Phosphorylation-Dependent Regulation of Invasion Markers in Human GSCs
(A and B) qRT-PCR analysis of invasion genes in hGSCs with pOLIG2high (BT145 and GB7) as compared to hGSCs with pOLIG2low (BT147 and GB16).
(C and D) qRT-PCR in BT147 and GB16 cells transduced with either control (shNT) or shOLIG2-expressing lentivirus.
(E) ChIP-seq tracks show TPN, TPM, Olig2, and H3K27ac signals at Tgfb2 loci (Mateo et al., 2015).
(F) Directed ChIP assay with anti-Olig2 and anti-H3K27ac to assess binding to Tgfb2 enhancer region in TPM- and TPN-expressing cells. Bar graph represents
fold change of TPM over TPN.
(G) ChIP-seq tracks from Suva` et al. (2014) show Olig2 and H3K27ac signals at TGFb2 loci.
(H) Directed ChIP assay for OLIG2 binding to TGFb2 enhancer region in represented hGSCs as compared to the non-target site (NT). Bar graphs represent fold
enrichment ofOLIG2over non-target (NT). For (A)–(D), F, andH, thedata representmean±SEMof three independent experiments. *p<0.05; **p<0.01; ***p<0.001.
See also Figure S5.
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Figure 6. SMAD2 Phosphorylation Is Inversely Correlated with the High Expression of pOLIG2
(A) Immunodetection of pSmad2 (green) in orthotopic tumors induced bymGSCs expressing TPM (upper) or TPN (lower) mutant. (A’) Right subpanels show higher
magnification images in the boxed area from (A).
(B) Quantification of pSmad2+ cells in TPN and TPM tumor tissues (cells from five independent fields from three tumor tissues each were counted).
(C) Representative images from immunostaining of consecutive patient GBM tissue sections with pSMAD2 (green) /Ki67 (red) and pSMAD2 (green) /OLIG2 (red)
antibodies. DAPI staining in blue.
(D) Western blot analysis of indicated hGSC lysates for pSMAD2 expression.
(E) Western blot analysis for OLIG2, pSMAD2, and SMAD2 after transduction with shNT or shOLIG2 lentivirus in GB16 cells.
(legend continued on next page)
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phosphorylation status of the CNS-specific factor OLIG2 regu-
lates glioma cell proliferation and invasion. Specifically, we
have discovered that unphosphorylated OLIG2 promotes glioma
invasion through the TGF-b2 signaling pathway.
Olig2 expression has been previously linked to migration/inva-
sion, both in normal and in malignant cells (Hornig et al., 2013;
Nevo et al., 2014; Siebzehnrubl et al., 2013). However, our report
demonstrates that the phosphorylation status of OLIG2 regu-
lates the switch from proliferation to invasion (Figure 7G).
Recently, two studies have reported the role of OLIG2 in glioma
invasion. Siebzehnrubl et al. (2013) have identified ZEB1 as a key
regulator of GBM invasion and stemness. These authors have
shown that ZEB1 upregulates expression of both EMT genes
and critical GSC markers like SOX2 and OLIG2. Consistent
with their observation, we have found that mGSCs expressing
TPN and hGSCs expressing pOLIG2low have high levels of inva-
sion genes, including ZEB1 (Figures 5 and S5). Furthermore, our
findings demonstrate that ZEB1 is a direct genetic target of
OLIG2, suggesting a cross-regulatory loop wherein unphos-
phorylated OLIG2 leads to increase in ZEB1, which, in turn, up-
regulates OLIG2 expression.
Another study has identified OLIG2 as one of the genes highly
expressed within the tumor cells in the invasive niche, but not at
the tumor core (Nevo et al., 2014). The authors have found that in
a single patient-matched tumor core versus rim, OLIG2 protein is
predominantly found at the tumor rim. In contrast, previous re-
ports (Venere et al., 2015) and our analysis of multiple human
GBM fresh frozen sections and GBM invasion TMA (containing
33 matched core, edge, and rim tumor tissues) reveal that
OLIG2-expressing cells are found both at the tumor core and
at the peritumoral rim (70% of tumors showed a strong signal
for OLIG2 at the core, edge, and rim) (Figure 4). It is plausible
that the presence of OLIG2+ cells at the tumor core and rim
depends on the tumor location and the molecular subtype of
the tumor. However, our analysis of more than 33 human GBM
tumors, as well as observations made by other laboratories
(Venere et al., 2015), suggests that OLIG2-expressing cells are
present throughout the tumor. In agreement with our observa-
tions, Nevo et al. (2014) have demonstrated that the knockdown
of OLIG2 leads to a decrease in expression of the EMT gene,
TWIST1.
The main question our data addresses is how OLIG2 can pro-
mote both proliferation and invasion. With the use of TPM and
TPN mutants, we have demonstrated that phosphorylation of
N-terminal serines in Olig2 decreases migration/invasion, both
in normal and in malignant neural progenitors, in vitro and in vivo
(Figures 1, 2, and 3). Our genetically relevant murine glioma
model allows us to dissect the role of Olig2 phosphorylation in
glioma invasion without the compounding effect of human ge-
netic and epigenetic heterogeneity in GBM. We have previously
shown that TPM-expressing glioma cells are highly proliferative
and tumorigenic and can form tumors, even following the injec-
tion of 100 cells (Sun et al., 2011). Here, we have provided evi-
dence for a role of unphosphorylated Olig2 in promoting tumor
invasion. TPN-expressing cells form highly invasive tumors,
wherein tumor cells show extensive infiltration of normal brain
at distant sites (Figures 3 and S3).This is not observed in TPM-
induced tumors. The only difference between these tumors is
the phosphorylation status of Olig2. Xenografts of hGSCs with
low levels of OLIG2 phosphorylation confirm our observations
with the murine glioma model. Based on our in vivo PDX data
and analysis of TMA, it seems likely that either of these two sce-
narios or a combination of the two exists: (1) distinct populations
of GSCs within a single tumor express pOLIG2high, pOLIG2low, or
no OLIG2 at all, and this expression is responsible for highly pro-
liferative (pOLIG2high), invasive OPC-like (OLIG2low), and astro-
cyte-like invasive (no OLIG2) cells, or (2) within the tumor cells,
OLIG2 expression and phosphorylation is modulated by the
location of the tumor and/or extracellular cues from the microen-
vironment and other tumor cells. Analysis of a small cohort of
hGSCs suggests that OLIG2 phosphorylation levels are lower
in the proneural subtype of GBMs, with PDGFRa expression
compared to the classical subtype with high EGFR levels (R.K.
and S.M., unpublished data). However, the ectopic overexpres-
sion of Olig2 phosphomutants in hGSCs suggests that altering
OLIG2 phosphorylation alone is capable of switching the pheno-
type from proliferative to invasive and vice versa, suggesting that
both scenarios might occur in GBM tumors.
The TGF-b pathway has been shown to play an important role
in invasion of tumor cells in several solid cancers, including GBM
(Anido et al., 2010; Rich, 2003; Weller et al., 2001; Wick et al.,
2001). Several studies have implicated the TGF-b pathway in gli-
oma pathobiology, with high levels of both TGF-b1 and TGF-b2
being found in GBM tumors compared to normal healthy brain
(Platten et al., 2001; Rich, 2003; Wick et al., 2001). Recently,
high levels of TGFb2 expression were reported to be correlated
with a poor prognosis in GBM patients (Rodo´n et al., 2014). Our
data provide evidence that TGF-b2 acts downstream of OLIG2
and is a critical player in promotingOLIG2-mediated glioma inva-
sion. hGSCswith pOLIG2low express high levels of pSMAD2 pro-
tein, which is one of the mediators of TGF-b signaling (Figure 6).
High levels of pSMAD2 expression in GSCs with low or unphos-
phorylated OLIG2 suggest that GBM tumor cells that have
pOLIG2low levels are inherently more invasive because of an
active TGF-b2 pathway.
Previous studies have demonstrated the importance of TGF-b
signaling in the maintenance of the mesenchymal stem-like
population in GBM cells (Anido et al., 2010). Our study provides
the mechanism involved in the regulation of TGF-b levels in
hGSCs through the modulation of OLIG2 phosphorylation (Fig-
ure 7). Overexpression of Olig2 phosphomutants (pOLIG2high)
suggests that the presence of pOLIG2 suppresses the invasion
program, in part through the suppression of TGFb2 signaling
pathway.
(F–H) Representative images of Ki67 and pSMAD2 immunostaining at core, edge, and rim regions in TMA-2 (F). IRS quantification of Ki67+ (red) (G) and pSMAD2+
(green) (H) cells at core, edge, and rim regions (see the Experimental Procedures for details). DAPI is in blue. Scale bars, 50 (A), 5 (A’) 100, (C) and 50 mm (F). For bar
graphs in (B), (G), and (H), data represent mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001.
See also Figure S6.
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OPCs are the major proliferating cell population in adult brain
(Dawson et al., 2003; Geha et al., 2010). Following brain injury,
OPCs migrate to the site of injury and contribute to scar forma-
tion and remyelination (Hughes et al., 2013). Given the fact that
Olig2 plays an important role in OPC specification, it is not sur-
prising that overexpression of Olig2 in OPCs enhancesmigration
(Hornig et al., 2013). Our data suggest that glioma cells exploit
Olig2’s normal role in OPC migration to invade and populate
normal brain parenchyma.
Collectively, our experimental findings provide insight into how
a single TF can lead to either tumor growth or invasion, depend-
ing on its phosphorylation state. The role of OLIG2 (a critical
factor for gliomagenic properties of GSCs) in GBM invasion pro-
vides strong support to the presence of glioma stem-like cells at
the invasive rim. The OLIG2+ therapy-resistant cells that evade
surgical resection could be the likely source of tumor recurrence
in GBM. Although therapies targeting glioma invasion alone have
shown no clinical benefit, our data provide strong support for
adjuvant therapies, in conjunction with anti-proliferative agents,
that can target invasive cells. Several agents targeting the TGF-b
pathway, including an antisense oligonucleotide against TGF-b2
(AP-12009), are currently being evaluated in clinical trials for
high-grade gliomas (Joseph et al., 2013). Future combination
studies with inhibitors of OLIG2 phosphorylation and the TGF-
b2 pathway will shed light on the therapeutic effectivenessof tar-
geting both pOLIG2 and unphosphorylated OLIG2.
EXPERIMENTAL PROCEDURES
Cell Culture
The patient samples used for this research were provided by the Biobank Core
Facility at St. Joseph’s Hospital and Medical Center and Barrow Neurological
Institute (BNI). The samples were deidentified and conformed to the Biobank
Institutional Review Board’s protocol. Patient-derived cell lines (GB3, GB7,
GB16, and GB42) were established from resected primary GBM tumor tissue
at BNI. BT145 and BT147 cells were obtained from K.L.L.’s laboratory at the
Dana-Farber Cancer Institute and propagated under similar conditions. Both
mGSCs and hGSCs were cultured, as described previously (Ligon et al.,
2007; Mehta et al., 2011). Tumor-bearing animals were euthanized at the onset
of neurological symptoms. See the Supplemental Experimental Procedures for
details.
Animal Experiments
Animal husbandry was performed in accordance with the guidelines of the
St. Joseph Hospital and Medical Center and Barrow Neurological Institute un-
der the protocol approved by the Institutional Animal Care and Use Commit-
tee. 5- to 6-week-old CrTac: NCr-Foxn1nu nude mice (Taconic Biosciences)
were used for in vivo orthotropic transplant of BT145, GB3, and GB16 cells.
Mouse tumor tissues derived from the injection of TPM and TPN-expressing
cells were obtained from Dr. Sun (C.D. Stiles laboratory) at the Dana-Farber
Cancer Institute. BT145 and BT147 xenograft tissues were obtained from
K.L.L.’s laboratory at the Dana-Farber Cancer Institute. For orthotopic trans-
plants, 2 ml of dissociated cells at a density of 100,000 cells/ml were injected
in the right striatum, as described previously (Ligon et al., 2007; Mehta et al.,
2011).
Tissue Processing and Cell Culture
Tissue was disaggregated using the gentleMACS Dissociator and enzymati-
cally digested with a Tumor Tissue Dissociation Kit with papain (Miltenyi Bio-
tec). Cells were plated at a density of 5 3 105 to 1 3 106 cells in Corning
non-tissue culture-treated 75-cm2 flasks. mNSCs, mGSCs, and hGSCs were
cultured as spheres on non-tissue culture-treated flasks or as adherent cul-
tures on laminin (Sigma-Aldrich) in DMEM/F12 media, supplemented with
B27 and N2 (Invitrogen; ThermoFisher Scientific) in the presence of 20 ng/ml
epidermal growth factor (EGF) and basic fibroblast growth factor (bFGF)
(EMD Millipore; Merck).
Immunofluorescence
For mouse brain tissue, immunofluorescence was performed on free-floating
sections (40 mm thickness), while for human, frozen tumor tissue sections
(5 mm thickness) were utilized. For TPN/TPM and BT145/BT147 FFPE
tumor tissues, 5-mm thickness sections were used. For immunodetection of
nuclear antigens, tissues were treated for 45 min in citrate buffer (pH 6) at
80C. For detailed staining procedures, see the Supplemental Experimental
Procedures.
Imaging
Analysis of immunostaining was performed on confocal stacks (with a step
size of 1 mm) acquired with a 203 oil-immersion objective on a laser-scanning
microscope (Leica; Leica Microsystems).
Analysis of Migratory Properties of GBM Lines
We injected 100,000 cells of two pOLIG2low lines (GB16 and GB3) and one
pOlig2high line (BT145) as described above. After 24 days, the mice (n = 3
per group) were sacrificed, and brains were fixed as described above.
Following 30% sucrose treatment, brains were frozen and cut into 40-mm sec-
tions using a cryostat. Sections were collected in 1:8 series so that in each se-
ries, consecutive sections were spatially separated by 280 mm. After staining
with anti-hMitochondria and anti-VIMENTIN, sections were mounted on
gelatin-coated slides (LabScientific) in a thorough antero-posterior anatomical
order. Cancer cells were identified by the co-expression of hMitochondria and
VIMENTIN. The maximum distance reached by GBM cells was calculated as
280 mm multiplied by the number of sections separating the section with a
visible needle track and the furthermost anterior and posterior sections con-
taining hMito+/VIM+ cells.
Real-Time PCR and ChIP Analysis
Total RNA was extracted from cells by using the RNeasy Purification Kit
(QIAGEN) in accordance with the manufacturer’s instructions. RNA was quan-
tified on a NanoDrop Spectrophotometer (Thermo Scientific; ThermoFisher
Figure 7. OLIG2 Promotes Glioma Invasion via the TGF-b2 Pathway
(A) Number of invading cells showing increased invasion following TGF-b2 addition or reduced invasion following TbRI treatment in less-invasive GB7 cells.
(B) Quantification showing reduced invasion following TbRI treatment in GB16 cells.
(C and D) Increase in invading GB7 cells in the presence of conditioned media from invasive GB16 (C). Increase in invading BT145 cells in the presence of
conditioned media from invasive BT147 cells (D). The addition of TbRI to conditioned media reduces invasion.
(E) GB16 cells show impaired invasion when transduced with TPM-expressing lentivirus compared to control eGFP virus.
(F) BT145 cells showed a significant increase in invasion when transduced with TPN-expressing lentivirus compared to eGFP control virus.
(G) Model of Olig2 phosphorylation-dependent glioma invasion. Our results suggest that when OLIG2 is phosphorylated at the N terminus, the TGF-b2 levels are
low, and hence there is no phosphorylation of SMAD2. Unphosphorylated OLIG2 triggers expression of TGF-b2, which then associates with TGF-bR1/2, resulting
in phosphorylation and nuclear localization of SMAD2 and eventual increase in invasion. For all graphs, data represent mean ± SD of three independent ex-
periments. *p < 0.05; **p < 0.01; ***p < 0.001).
See also Figure S7.
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Scientific), and 1 mg of total RNA was used for cDNA synthesis by using the
SuperScript III Kit (Life Technologies). qPCR was performed using inventoried
TaqMan assays for respective target genes and housekeeping control genes
(HPRT or 18S) on the QuantStudio 6 Flex Real-Time PCR System (Life Tech-
nologies; ThermoFisher Scientific). ChIP experiments were performed as
described previously (Meijer et al., 2014). Primer details are provided in the
Supplemental Experimental Procedures.
GBM Subtype Classification of Human GSCs
Human GSC lines from K.L.L.’s laboratory (BT145 and BT147) have been clas-
sified by genetic mutations, microarray analysis, and array CGH analysis. GB
lines have been classified by qRT-PCR analysis of genes associated with each
subtype (Verhaak et al., 2010) using inventoried Taqman assays (PDGFRa,
DLL3, OLIG2, PTEN, TOP2A, EGFR, CD44, and CHI3L1). It is important to
note that Table S1 indicates the proteins levels of OLIG2. IDH1mutation status
was confirmed by the pathology department at St. Joseph’s Hospital and
Medical Center by immunohistochemistry with anti-IDH1R132H antibody.
Samples were classified into a particular subtype by the expression of most
markers within a subtype.
Cell Migration and Invasion Assay
For determination of migration capacity, 10,000 cells/well (mNSC, mGSC and
hGSC) were seeded on the laminin-coated 96-well Oris Cell Seeding Stoppers
or on anOris (BCG) plate (Platypus Technologies). The stoppers were removed
after 2 hr, and additional media with growth factors were added to the wells.
The migration of cells to the detection zone was analyzed after 24 hr. Cells
were imaged using bright-field microscopy. Images were then analyzed for
cell migration using ImageJ software (NIH, U.S. Department of Health and Hu-
man Services). The invasion potential was determined on collagen-coated
transwell inserts with a pore size of 8 mm (Becton Dickinson). Dissociated cells
(100,000/well for mNSC or mGSC) and (50,000/well for hGSC) were resus-
pended in serum-free media with growth factors (20 ng/ml EGF and bFGF
each) and mixed with thawed Matrigel (BD Biosciences). A total of 50 ml of
Matrigel plus cells suspension was transferred to transwells and inserted in
triplicates; transwells were then placed in 24-well plates. After 24 (for hGSC)
or 48 hr (for mNSC or mGSC), invaded cells that accumulated on the
bottom surface of the transwell insert membrane were fixed with 4% PFA
(paraformaldehyde) for 20 min and stained with DAPI for 1 min. The mem-
branes were subsequently cut out and mounted on microscopic slides for
quantification. Representative pictures of the membranes with cells were
acquired at 103 or 203 magnifications, and the total number of cells in five
individual fields per membrane was counted; the mean ± SD number of
invading cells for every condition was calculated. Cells were treated with
TGF-b2 (10 ng/ml; GIBCO; ThermoFisher Scientific) and/or the small-molecule
inhibitor of TbRI/II, LY2109761 (2 mM; ApexBio Technology; Fisher Scientific;
ThermoFisher Scientific).
Quantification of TGF-b2 by ELISA
Levels of TGF-b2 secreted bymurine or human cells in cell-culture media were
measured using sandwich ELISA (Quantikine mouse TGF-b2 and Quantikine
human TGF-b-2; R&D Systems) in accordance with the manufacturer’s proto-
col. Cells were seeded (1 3 105 cells/well, 24-well plates) on laminin-coated
plates and incubated for 36 hr. The values were expressed as nanograms
per milligram of protein.
TMA Staining and Analysis
Glioma invasion tissue microarrays (TMAs) were obtained fromM.E.B. labora-
tory at TGen (Kislin et al., 2009). Slides were deparaffinized and hydrated, fol-
lowed by heat-mediated antigen retrieval in 10 mM citrate buffer (pH 6) at
80C, and subsequently immunostained with fluorescence-conjugated anti-
bodies as described above. For each immunostaining, TMA were imaged
with a 203 oil-immersion objective. In this study 33 patient tumor tissues on
the TMA were used for the analysis of the percentage of positive cells at the
core, rim, or edge. The closest H&E section from the TMA was reviewed by
Dr. Jennifer Eschbacher, a board-certified neuropathologist at the St. Jo-
seph’sHospital &Medical Center. The TMA imageswere assessed and scored
in accordance with the semiquantitative scoring system to obtain the immuno-
reactive score (IRS) (Remmele and Stegner, 1987). For evaluation of the stain-
ing patterns, the percentage of positive cells (PP; zero points: no positive cells,
one point: 1%–10%, two points: 10%–20%, three points; >20%) and the stain-
ing intensity (SI; 0 point: no signal, 1 point: weak, 2 point: moderate, 3 point;
strong) was determined and added. The average IRS score was plotted for
each staining.
Statistical Analyses
Data are presented as the mean ± SD or as the mean ± SEM. If comparing two
conditions or cell lines, significance was tested with unpaired two-tailed
Student’s t test. Significance of the differences between conditions or cell
lines was tested by the two-way ANOVA with Bonferroni multiple comparison
tests using GraphPad Prism software. Statistical significance was defined as
p < 0.05.
For detailed methods, see the Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
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